Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cagrilintide vs Pramlintide (Symlin)
An educational, source-based comparison of Cagrilintide and Pramlintide (Symlin) — how each peptide works, what it's researched for, and what to know before going deeper.
A long-acting analog of amylin, a pancreatic hormone co-secreted with insulin. It slows gastric emptying, increases satiety, and suppresses glucagon — complementary to GLP-1 mechanisms.
- Weight management as monotherapy and combined with semaglutide (CagriSema)
- Glycemic control in type 2 diabetes
- • Investigational; not yet FDA-approved as monotherapy.
- • GI side effects similar to GLP-1 agonists.
Synthetic analog of the pancreatic hormone amylin. Slows gastric emptying, suppresses inappropriate postprandial glucagon, and increases satiety as adjunct to insulin.
- Type 1 diabetes (with insulin)
- Type 2 diabetes on insulin
- • FDA-approved.
- • Boxed warning: severe insulin-induced hypoglycemia.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Cagrilintide | Cagrilintide plus semaglutide for obesity (Phase 2) | The Lancet | 2021 | Combination produced greater weight loss than either agent alone. |
| Pramlintide (Symlin) | Pramlintide in T1D | Diabetes Care | 2003 | Improved A1c and reduced postprandial glucose excursions. |
Side-effect & safety grid
- Investigational; not yet FDA-approved as monotherapy.
- GI side effects similar to GLP-1 agonists.
- FDA-approved.
- Boxed warning: severe insulin-induced hypoglycemia.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Cagrilintide vs Pramlintide (Symlin) — Key differences
- Class: Cagrilintide is classified as Metabolic · Amylin, while Pramlintide (Symlin) is Amylin Analog · Metabolic.
- Primary research focus: Cagrilintide — weight management as monotherapy and combined with semaglutide (cagrisema); Pramlintide (Symlin) — type 1 diabetes (with insulin).
- Tag: Weight loss vs FDA-Approved · Metabolic.